Fuzziness in the core of the human pathogenic viruses HCV and HIV

Advances in Experimental Medicine and Biology

Volumn 725, Issue , 2012, Pages 142-158

  Ivanyi Nagy, Roland ^a   Darlix, Jean Luc ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b University Lyon i   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORE PROTEIN; GAG PROTEIN; MYRISTIC ACID; VIRUS DNA; VIRUS NUCLEOPROTEIN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; CRYSTALLIZATION; DNA INTEGRATION; GENETIC VARIABILITY; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; PROTEIN LOCALIZATION; PROTEIN RNA BINDING; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; VIRUS ASSEMBLY; VIRUS MORPHOGENESIS; VIRUS PARTICLE; VIRUS PATHOGENESIS; VIRUS REPLICATION; CHEMISTRY; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; PHYSIOLOGY; REVIEW; VIRION;

CARANGIDAE; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

HEPACIVIRUS; HIV-1; HUMANS; VIRAL CORE PROTEINS; VIRION;

EID: 84859487519     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0659-4_9     Document Type: Article

References (133)

1. Ward JJ, Sodhi JS, McGuffin LJ et al. Prediction and functional analysis of native disorder in proteins from the three kingdoms of life. J Mol Biol 2004; 337(3):635-645.
2. DunkerAK, Obradovic Z, Romero P et al. Intrinsic protein disorder in complete genomes. Genome Inform Ser Workshop Genome Inform 2000; 11:161-171.
3. Mohan A, Sullivan WJ Jr., Radivojac P et al. Intrinsic disorder in pathogenic and nonpathogenic microbes: discovering and analyzing the unfoldomes of early-branching eukaryotes. MolBiosyst 2008; 4(4):328-340.
4. Xie H, Vucetic S, Iakoucheva LM et al. Functional anthology of intrinsic disorder. 3. Ligands, posttranslational modifications and diseases associated with intrinsically disordered proteins. J Proteome Res 2007;6(5):1917-1932.
5. Xie H, Vucetic S, Iakoucheva LM et al. Functional anthology of intrinsic disorder. 1. Biological processes and functions of proteins with long disordered regions. J Proteome Res 2007; 6(5):1882-1898.
6. Dosztanyi Z, Chen J, DunkerAK et al. Disorderand sequence repeats in hub proteins and their implications for network evolution. J Proteome Res 2006; 5(11):2985-2995.
7. Haynes C, Oldfield CJ, Ji F et al. Intrinsic disorder is a common feature of hub proteins from four eukaryotic interactomes. PLoS Comput Biol 2006; 2(8):e100.
8. Morellet N, de Rocquigny H, Mely Y et al. Conformational behaviour of the active and inactive forms of the nucleocapsid NCp7 of HIV-1 studied by 1H NMR. J Mol Biol 1994;235(1):287-301.
9. Morellet N, Jullian N, De Rocquigny H et al. Determination of the structure of the nucleocapsid protein NCp7 from the human immunodeficiency virus type 1 by 1H NMR. EMBO J 1992; 11(8):3059-3065.
10. Goh GK, Dunker AK, Uversky VN. Protein intrinsic disordertoolbox for comparative analysis of viral proteins. BMC Genomics 2008; 9 Suppl 2:S4.
11. Longhi S, Oglesbee M. Structural disorder within the measles virus nucleoprotein and phosphoprotein. Protein Pept Lett 2010; 17(8):961-978.
12. Reingewertz TH, Shalev DE, FriedlerA. Structural disorder in the HIV- 1Vifprotein and interaction-dependent gain of structure. Protein Pept Lett 2010; 17(8):988-998.
13. Shojania S,O'Neil JD. Intrinsic disorder and function of the HIV-1 Tatprotein. Protein Pept Lett 17(8):999-1011.
14. Ivanyi-Nagy R, Darlix JL. Intrinsic disorder in the core proteins of flaviviruses. Protein Pept Lett 2010; 17(8):1019-1025.
15. Chang CK, Hsu YL, Chang YH et al. Multiple nucleic acid binding sites and intrinsic disorder of severe acute respiratory syndrome coronavirus nucleocapsid protein: implications for ribonucleocapsid protein packaging. J Virol 2009; 83(5):2255-2264.
16. Chang CK, Sue SC, Yu TH et al. Modular organization of SARS coronavirus nucleocapsid protein. J Biomed Sci 2006; 13(1):59-72.
17. Lindenbach B, Thiel HJ, Rice CM. Flaviviridae: The Viruses and Their Replication. Fields Virology. Philadelphia: Lippincott-Raven Publishers; 2007:1101-1152.
18. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5(9):558-567.
19. Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29 Suppl 1:74-81.
20. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36(5 Suppl 1):S21-29.
21. Galossi A, Guarisco R, Bellis Letal. Extrahepatic manifestations of chronic HCV infection. J Gastrointestin Liver Dis 2007; 16(1):65-73.
22. Acharya JN, Pacheco VH. Neurologic complications of hepatitis C. Neurologist 2008; 14(3):151-156.
23. Bartenschlager R, Frese M, Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 2004; 63:71-180.
24. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5(6):453-463.
25. Hijikata M, Kato N, Ootsuyama Y et al. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci USA 1991; 88(13):5547-5551.
26. McLauchlan J, Lemberg MK, Hope G et al. Intramembrane proteolysis promotes traficking of hepatitis C virus core protein to lipid droplets. EMBO J 2002; 21(15):3980-3988.
27. Hope RG, McLauchlan J. Sequence motifs required for lipid droplet association and protein stability are unique to the hepatitis C virus core protein. J Gen Virol 2000; 81(Pt 8):1913-1925.
28. Santolini E, Migliaccio G, LaMonica N. Biosynthesis and biochemical properties of the hepatitis C virus core protein. J Virol 1994; 68(6):3631-3641.
29. Cristofari G, Ivanyi-Nagy R, Gabus C et al.The hepatitis C virus Core protein is apotent nucleic acid chaperone that directs dimerization of the viral (+) strand RNA in vitro. Nucleic Acids Res 2004; 32(8):2623-2631.
30. Majeau N, Gagne V, Boivin A et al. The N-terminal half of the core protein of hepatitis C virus is sufficient for nucleocapsid formation. J Gen Virol 2004; 85(Pt 4):971-981.
31. Kunkel M, Lorinczi M, Rijnbrand R et al. Self-assembly of nucleocapsid-like particles from recombinant hepatitis C virus core protein. J Virol 2001; 75(5):2119-2129.
32. Kunkel M, Watowich SJ. Conformational changes accompanying self-assembly of the hepatitis C virus core protein. Virology 2002; 294(2):239-245.
33. Ivanyi-Nagy R, Lavergne JP, Gabus C et al. RNA chaperoning and intrinsic disorder in the core proteins of Flaviviridae. Nucleic Acids Res 2008; 36(3):712-725.
34. Boulant S, Vanbelle C, Ebel C et al. Hepatitis C virus core protein is a dimeric alpha-helical protein exhibiting membrane protein features. J Virol 2005; 79(17):11353-11365.
35. Duvignaud JB, Savard C, Fromentin R etal. Structure and dynamics of the N-terminal half of hepatitis C virus core protein: an intrinsically unstructured protein. Biochem Biophys Res Commun 2009;378(1):27-31.
36. Ivanyi-Nagy R, Kanevsky I, Gabus C et al. Analysis ofhepatitis C virus RNA dimerization and core-RNA interactions. Nucleic Acids Res 2006; 34(9):2618-2633.
37. Miyanari Y, Atsuzawa K, Usuda N et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007; 9(9):1089-1097.
38. Namba K, Stubbs G. Structure of tobacco mosaic virus at 3.6 A resolution: implications for assembly. Science 1986; 231(4744):1401-1406.
39. Butler PJ. Self-assembly of tobacco mosaic virus: the role of an intermediate aggregate in generating both specificity and speed. Philos Trans R Soc Lond B Biol Sci 1999; 354(1383):537-550.
40. Fraenkel-Conrat H, Williams RC. Reconstitution of Active Tobacco Mosaic Virus from Its Inactive Protein and Nucleic Acid Components. Proc Natl Acad Sci USA 1955; 41(10):690-698.
41. Tompa P, Fuxreiter M. Fuzzy complexes: polymorphism and structural disorder in protein-protein interactions. Trends Biochem Sci 2008; 33(1):2-8.
42. Boulant S, Montserret R, Hope RG et al. Structural determinants that target the hepatitis C virus core protein tolipid droplets. J Biol Chem 2006; 281(31):22236-22247.
43. Majeau N, Fromentin R, Savard C et al. Palmitoylation ofhepatitis C virus core protein isimportant for virion production. J Biol Chem 2009.
44. Ivanyi-Nagy R, Davidovic L, Khandjian EW et al. Disordered RNA chaperone proteins: from functions to disease. Cell Mol Life Sci 2005; 62(13):1409-1417.
45. ZunigaS, Sola I, Cruz JL etal. Role of RNA chaperones in virus replication. Virus Res 2009; 139(2):253-266.
46. Tompa P, Csermely P. The role of structural disorder in the function of RNA and protein chaperones. FASEB J 2004; 18(11):1169-1175.
47. Kuhn RJ, Zhang W, Rossmann MG et al. Structure of dengue virus: implications for flavivirus organization, maturation and fusion. Cell 2002; 108(5):717-725.
48. Mukhopadhyay S, Kim BS, Chipman PR et al. Structure of West Nile virus. Science 2003; 302(5643):248.
49. Zhang Y, Corver J, Chipman PR et al. Structures of immature flavivirus particles. EMBO J 2003; 22(11):2604-2613.
50. Murray CL, Marcotrigiano J, Rice CM. Bovine viral diarrhea virus core is an intrinsically disordered protein that binds RNA. J Virol 2008; 82(3):1294-1304.
51. Moriya K, Fujie H, Shintani Y et al. The core protein ofhepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4(9):1065-1067.
52. Moriya K, Yotsuyanagi H, Shintani Y et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997; 78 ( Pt 7):1527-1531.
53. Lerat H, Honda M, Beard MR et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins ofhepatitis C virus. Gastroenterology 2002; 122(2):352-365.
54. Shintani Y,Fujie H, Miyoshi H et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126(3):840-848.
55. Liang TJ, Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 1):S62-71.
56. McLauchlan J. Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes. J Viral Hepat 2000; 7(1):2-14.
57. Ray RB, Ray R. Hepatitis C virus core protein: intriguing properties and functional relevance. FEMS Microbiol Lett 2001; 202(2):149-156.
58. de Chassey B, Navratil V, Tafforeau L etal. Hepatitis Cvirus infection protein network. Mol Syst Biol 2008;4:230.
59. Navratil V,de Chassey B,Meyniel Let al. VirHostNet:aknowledge base forthe management and the analysis ofproteome-wide virus-host interactionnetworks. Nucleic Acids Res 2009; 37(Databaseissue):D661-668.
60. Del Campo JA, Romero-Gomez M. Steatosis and insulin resistance in hepatitis C: a way out for the virus? World J Gastroenterol 2009; 15(40):5014-5019.
61. Birerdinc A, Afendy A, Stepanova M et al. Functional pathway analysis ofgenes associated with response to treatment for chronic hepatitis C. J Viral Hepat 2009.
62. Koike K, Moriya K, Matsuura Y. Animal models for hepatitis C and related liver disease. Hepatol Res 40(1):69-82.
63. Miyamoto H, Moriishi K, Moriya K et al. Involvement of the PA28gamma-dependent pathway in insulin resistance induced by hepatitis C virus core protein. J Virol 2007; 81(4):1727-1735.
64. Moriishi K, Mochizuki R, Moriya K et al. Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci USA 2007; 104(5):1661-1666.
65. Moriishi K, Okabayashi T, Nakai K et al. Proteasome activator PA28gamma-dependent nuclear retention and degradation of hepatitis C virus core protein. J Virol 2003; 77(19):10237-10249.
66. Kriwacki RW, Hengst L, Tennant L et al. Structural studies of p21Waf1/Cip1/Sdi1 inthefreeandCdk2-bound state: conformational disorder mediates binding diversity. Proc Natl Acad Sci USA 1996;93(21):11504-11509.
67. Dyer MD, Murali TM, Sobral BW. The landscape of human proteins interacting with viruses and other pathogens. PLoS Pathog 2008; 4(2):e32.
68. Temin HM. Sex and recombination in retroviruses. Trends Genet 1991; 7(3):71-74.
69. Chen J, Nikolaitchik O, Singh J et al. High eficiency ofHIV-1 genomic RNA packaging and heterozygote formation revealed by single virion analysis. Proc Natl Acad Sci USA 2009; 106(32):13535-13540.
70. Cofin JM. Structure, replication and recombination of retrovirus genomes: some unifying hypotheses. J Gen Virol 1979; 42(1):1-26.
71. Cofin JM. Retroviridae and their replication. In: Fields B, Knipe D, Chanock R, eds. Virology Vol I. New York: Raven Press; 1990:1437-1500.
72. Gilboa E, Mitra SW, Goff S et al. A detailed model of reverse transcription and tests of crucial aspects. Cell 1979; 18(1):93-100.
73. Lewinski MK, Bushman FD. Retroviral DNA integration-mechanism and consequences. Adv Genet 2005; 55:147-181.
74. Wainberg MA, Jeang KT. 25 years of HIV-1 research-progress and perspectives. BMC Med 2008; 6:31.
75. Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res85(1):1-18.
76. Jones KA. HIV trans-activation and transcription control mechanisms. New Biol 1989; 1(2):127-135.
77. Yilmaz A, Bolinger C, Boris-Lawrie K. Retrovirus translation initiation: Issues and hypotheses derived from study of HIV-1. Curr HIV Res 2006; 4(2):131-139.
78. Darlix JL, Garrido JL, Morellet N et al. Properties, functions and drug targeting of the multifunctional nucleocapsid protein ofthe human immunodeiciency virus. Adv Pharmacol 2007; 55:299-346.
79. Darlix JL, Lapadat-Tapolsky M,de Rocquigny H et al. First glimpses at structure-function relationships of the nucleocapsid protein of retroviruses. J Mol Biol 1995; 254(4):523-537.
80. Berkhout B. Structure and function of the human immunodeiciency virus leader RNA. Prog Nucleic Acid Res Mol Biol 1996; 54:1-34.
81. Levin JG, Guo J, Rouzina I et al. Nucleic acid chaperone activity of HIV-1 nucleocapsid protein: critical role in reverse transcription and molecular mechanism. Prog Nucleic Acid Res Mol Biol 2005; 80:217-286.
82. Rein A, Henderson LE, Levin JG. Nucleic-acid-chaperone activity of retroviral nucleocapsid proteins: significance for viral replication. Trends Biochem Sci 1998; 23(8):297-301.
83. Kleiman L, Halwani R, Javanbakht H. The selective packaging and annealing of primer tRNALys3 in HIV-1. Curr HIV Res 2004; 2(2):163-175.
84. De Guzman RN, Wu ZR, Stalling CC et al. Structure of the HIV-1 nucleocapsid protein bound to the SL3 psi-RNA recognition element. Science 1998; 279(5349):384-388.
85. de Rocquigny H, Shvadchak V, Avilov S et al. Targeting the viral nucleocapsid protein in anti-HIV-1 therapy. Mini Rev Med Chem 2008; 8(1):24-35.
86. Thomas JA, Gorelick RJ. Nucleocapsid protein function in early infection processes. Virus Res 2008; 134(1-2):39-63.
87. Grigorov B, Decimo D, Smagulova F et al. Intracellular HIV-1 Gag localization is impaired by mutations in the nucleocapsid zinc ingers. Retrovirology 2007; 4:54.
88. Tanchou V, Decimo D, Pechoux C et al. Role of the N-terminal zinc inger of human immunodeiciency virus type 1 nucleocapsid protein in virus structure and replication. J Virol 1998; 72(5):4442-4447.
89. Cristofari G, Darlix JL. The ubiquitous nature of RNA chaperone proteins. Prog Nucleic Acid Res Mol Biol 2002; 72:223-268.
90. Goff SP. Host factors exploited by retroviruses. Nat Rev Microbiol 2007; 5(4):253-263.
91. Freed EO. HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 1998; 251(1):1-15.
92. Freed EO. Viral late domains. J Virol 2002; 76(10):4679-4687.
93. Balvay L, Lopez Lastra M, Sargueil B, Darlix JL, Ohlmann T. Translational control of retroviruses. Nat Rev Microbiol 2007; 5(2):128-140.
94. Kuciak M, Gabus C, Ivanyi-Nagy R et al. The HIV-1 transcriptional activator Tat has potent nucleic acid chaperoning activities in vitro. Nucleic Acids Res 2008; 36(10):3389-3400.
95. Cimarelli A, Darlix JL. Assembling the human immunodeiciency virus type 1. Cell Mol Life Sci 2002; 59(7):1166-1184.
96. Ganser-Pornillos BK, Yeager M, Sundquist WI. The structural biology of HIV assembly. Curr Opin Struct Biol 2008; 18(2):203-217.
97. Mangeot PE, Negre D, Dubois B et al. Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells. J Virol 2000; 74(18):8307-8315.
98. Negre D, Duisit G, Mangeot PE etal. Lentiviral vectors derived from simian immunodeficiency virus. Curr Top Microbiol Immunol 2002; 261:53-74.
99. Saad JS, Loeliger E, Luncsford P et al. Point mutations in the HIV-1 matrix protein turn off the myristyl switch. J Mol Biol 2007; 366(2):574-585.
100. Saad JS, Miller J, Tai J et al. Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly. Proc Natl Acad Sci USA 2006; 103(30):11364-11369.
101. Raposo G, Moore M, Innes D et al. Human macrophages accumulate HIV-1 particles in MHC II compartments. Traffic 2002; 3(10):718-729.
102. Grigorov B, Arcanger F, Roingeard P et al. Assembly of infectious HIV-1 in human epithelial and T-lymphoblastic cell lines. J Mol Biol 2006; 359(4):848-862.
103. Ono A, Freed EO. Cell-type-dependent targeting of human immunodeiciency virus type 1 assembly to the plasma membrane and the multivesicular body. J Virol 2004; 78(3):1552-1563.
104. Ono A, Freed EO. Role of lipid rafts in virus replication. Adv Virus Res 2005; 64:311-358.
105. Hamard-Peron E, Juillard F, Saad JS et al. Targeting of murine leukemia virus gag to the plasma membrane is mediated by PI(4,5)P2/PS and a polybasic region in the matrix. J Virol 84(1):503-515.
106. Demirov DG, Freed EO. Retrovirus budding. Virus Res 2004; 106(2):87-102.
107. Morita E, Sundquist WI. Retrovirus budding. Annu Rev Cell Dev Biol 2004; 20:395-425.
108. Popov S, Popova E, Inoue M et al. Divergent Bro1 domains share the capacity to bind human immunodeiciency virus type 1 nucleocapsid and to enhance virus-like particle production. J Virol 2009; 83(14):7185-7193.
109. FujiiK,MunshiUM,AblanSDetal.FunctionalroleofAlixinHIV-1replication. Virology2009;391(2):284-292.
110. Gabus C, Auxilien S, Pechoux C et al. The prion protein has DNA strand transfer properties similar to retroviral nucleocapsid protein. J Mol Biol 2001; 307(4):1011-1021.
111. Buckman JS, Bosche WJ, Gorelick RJ. Human immunodeficiency virus type 1 nucleocapsid zn(2+) fingers are required for efficient reverse transcription, initial integration processes and protection of newly synthesized viral DNA. J Virol 2003; 77(2):1469-1480.
112. Berthoux L, PechouxC, OttmannM etal. Mutations inthe N-terminal domainofhumanimmunodeiciencyvirus type 1 nucleocapsidproteinaffectvirioncore structureandproviralDNAsynthesis. JVirol1997;71(9):6973-6981.
113. BampiC,BibilloA,WendelerMetal.Nucleotideexcisionrepairandtemplate- independentadditionbyHIV-1 reverse transcriptase in the presence of nucleocapsid protein. J Biol Chem 2006; 281(17):11736-11743.
114. Carteau S, Gorelick RJ, Bushman FD. Coupled integration of human immunodeficiency virus type 1 cDNA endsbypurifiedintegraseinvitro: stimulationbytheviralnucleocapsidprotein.JVirol 1999;73(8):6670-6679.
115. Hu WS, Temin HM. Genetic consequences of packaging two RNA genomes in one retroviral particle: pseudodiploidyand high rate ofgeneticrecombination. Proc Natl Acad Sci USA 1990; 87(4):1556-1560.
116. Cheng Y, LeGall T, Oldield CJ et al. Rational drug design via intrinsically disordered protein. Trends Biotechnol 2006; 24(10):435-442.
117. Csermely P, Agoston V, Pongor S. The eficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 2005; 26(4):178-182.
118. ObradovicZ, Peng K, Vucetic S et al. Predicting intrinsic disorder from amino acid sequence. Proteins 2003; 53 Suppl 6:566-572.
119. Freed EO.HIV-1 Gag: flipped out for PI(4,5)P(2). Proc Natl Acad Sci USA 2006; 103(30):11101-11102.
120. Adamson CS, Freed EO.Human immunodeiciency virus type 1 assembly, release and maturation. Adv Pharmacol 2007; 55:347-387.
121. Lopez-VergesS,CamusG,BlotGetal. Tail- interactingproteinTIP47isaconnectorbetweenGagandEnvand is requiredfor Env incorporation into HIV-1 virions. Proc Natl Acad Sci USA 2006; 103(40):14947-14952.
122. Paillart JC, Shehu-Xhilaga M, Marquet R et al. Dimerization of retroviral RNA genomes: an inseparable pair. Nat Rev Microbiol 2004; 2(6):461-472.
123. Lavallee C, Yao XJ, Ladha A et al. Requirement ofthe Pr55gag precursor for incorporation ofthe Vpr product into human immunodeiciency virus type 1 viral particles. J Virol 1994; 68(3):1926-1934.
124. Mougel M, Houzet L, Darlix JL. Whenisit time for reverse transcription to start and go? Retrovirology2009;6:24.
125. Garrus JE, von Schwedler UK, Pornillos OW et al. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 2001; 107(1):55-65.
126. VerPlank L, Bouamr F, LaGrassa TJ et al. Tsg101, ahomologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc Natl Acad Sci USA 2001; 98(14):7724-7729.
127. Pettit SC, Lindquist JN, Kaplan AH et al. Processing sites in the human immunodeiciency virus type 1 (HIV-1)Gag-Pro- Polprecursorarecleavedbytheviralproteaseatdifferentrates. Retrovirology2005; 2:66.
128. Pettit SC, Moody MD, Wehbie RS et al. The p2 domain of human immunodeiciency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol 1994; 68(12):8017-8027.
129. Fu W, Dang Q, Nagashima K et al. Effects of Gag mutation and processing on retroviral dimeric RNA maturation. J Virol 2006; 80(3):1242-1249.
130. WolfD,Goff SP. Hostrestrictionfactorsblockingretroviralreplication. AnnuRev Genet 2008; 42:143-163.
131. GoncalvesJ,Santa-MartaM.HIV-1VifandAPOBEC3G:multipleroadstoonegoal. Retrovirology2004;1:28.
132. Martinez-Picado J, Martinez MA. HIV-1 reverse transcriptase inhibitor resistance mutations and itness: a view from theclinicand exvivo. Virus Res 2008; 134(1-2):104-123.
133. Wlodawer A, Vondrasek J. Inhibitors of HIV-1 protease: amajor success ofstructure-assisted drug design. Annu Rev Biophys Biomol Struct 1998; 27:249-284.